Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05149456
Other study ID # 8373
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 15, 2021
Est. completion date August 31, 2022

Study information

Verified date November 2021
Source University Hospital, Strasbourg, France
Contact Dominique STEPHAN, MD, PhD
Phone 33 3 69 55 09 52
Email dominique.stephan@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The cardiovascular risk of women has been the subject of particular interest in recent years, in the world, in particular under the impetus of Cardiology companies, with more and more work focusing on the specificities of these diseases in women as well as differences in terms of management and prognosis with a literature mainly based on American data and which focuses particularly on ischemic heart disease. The expected results are to have a prevalence of PAOD in an Alsatian cohort, most of the data we currently have from American data, with analysis of the impact of specific and non-specific risk factors in this cohort and their weight in PAOD.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date August 31, 2022
Est. primary completion date August 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion criteria: - Adult woman (=18 years old) - Patient hospitalized in an Intensive Cardiology Unit (ICU) at the HUS for a type 1 myocardial infarction confirmed according to the criteria of the fourth universal definition of the ESC between 01/01/2021 to 30/06/2021 inclusive - Patient who did not express her opposition to the reuse of her data for scientific research purposes. Exclusion criteria: - Patient who expressed her opposition to participating in the study - Impossibility of providing the subject with enlightened information (difficulties in understanding the subject, MMS <20/30…) - Non-type 1 or unconfirmed myocardial infarction - Unstable or refractory shock state at the time of the echodoppler examination - Complication of the coronary angiography approach, in the case of femoral approach only, requiring surgical management. - Patient under curatorship, guardianship or judicial safeguard.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Service des Maladies VASC-HTA-Pharmacologie Clinique - Hôpitaux Universitaires de Strasbourg Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Study of the prevalence of peripheral artery occlusive disease (PAOD) Files analysed retrospectively from January 01, 2021 to Jun 30, 2021 will be examined]
See also
  Status Clinical Trial Phase
Recruiting NCT03668353 - Recombinant SeV-hFGF2/dF Injection for PAOD Phase 1